Details for Patent: 8,404,697
✉ Email this page to a colleague
Title: | Quinazoline derivatives for the treatment of cancer diseases |
Abstract: | The present invention relates to the use of quinazolines of formula (I), wherein the groups R.sup.a to R.sup.d have the meanings given in the claims and specification, in cancer therapy. ##STR00001## |
Inventor(s): | Solca; Flavio (Vienna, AT), Amelsberg; Andree (Danbury, CT), Stehle; Gerd (Ehingen, DE), Van Meel; Jacobus C. A. (Moedling, AT), Baum; Anke (Vienna, AT) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Filing Date: | Nov 09, 2006 |
Application Number: | 12/093,321 |
Claims: | 1. A method for treating Non-small cell lung cancer (NSCLC) in a patient, wherein the patient has an activating EGFR mutation in the tyrosine kinase domain of the EGF receptor and/or an activating HER2 mutation, and the patient has acquired or persistent resistance to gefitinib or erlotinib treatment, comprising administering a therapeutically effective amount of an EGFR inhibitor to the patient, wherein said inhibitor is the compound (d) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline ##STR00012## or physiologically acceptable salt thereof. 2. The method of claim 1, wherein the compound is (d') 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]-amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate. |